Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GOSS logo GOSS
Upturn stock ratingUpturn stock rating
GOSS logo

Gossamer Bio Inc (GOSS)

Upturn stock ratingUpturn stock rating
$1.31
Delayed price
Profit since last BUY35.05%
upturn advisory
Strong Buy
BUY since 29 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: GOSS (3-star) is a STRONG-BUY. BUY since 29 days. Profits (35.05%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 23.97%
Avg. Invested days 26
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 296.85M USD
Price to earnings Ratio -
1Y Target Price 7.61
Price to earnings Ratio -
1Y Target Price 7.61
Volume (30-day avg) 1260215
Beta 1.96
52 Weeks Range 0.50 - 1.60
Updated Date 02/13/2025
52 Weeks Range 0.50 - 1.60
Updated Date 02/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.25

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -68.03%
Operating Margin (TTM) -357.8%

Management Effectiveness

Return on Assets (TTM) -11.24%
Return on Equity (TTM) -90.26%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 173443419
Price to Sales(TTM) 2.82
Enterprise Value 173443419
Price to Sales(TTM) 2.82
Enterprise Value to Revenue 1.65
Enterprise Value to EBITDA -0.39
Shares Outstanding 226604000
Shares Floating 187954535
Shares Outstanding 226604000
Shares Floating 187954535
Percent Insiders 3.29
Percent Institutions 82.07

AI Summary

Gossamer Bio Inc.: A Comprehensive Overview

Company Profile:

History and Background:

Gossamer Bio, Inc. (NASDAQ: GOSS) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2012, the company focuses on discovering, developing, and commercializing novel therapies for the treatment of severe metabolic, inflammatory, and oncological diseases.

Core Business Areas:

Gossamer's primary focus is on developing innovative therapies targeting the lysosomal pathway, a complex system critical for cellular waste disposal and recycling. The company's pipeline includes programs in areas like Gaucher disease, Neuronal Ceroid Lipofuscinosis type 2 (NCL2), and cancer.

Leadership and Structure:

The company is led by a team of experienced executives in the pharmaceutical and biotechnology industries. Dr. Shehnaaz Suliman serves as the President and CEO, joined by Dr. Babak Hemmati as Chief Medical Officer and Dr. David Gobbi as Chief Technology Officer. They guide the company with a Board of Directors comprising industry veterans and investors.

Top Products and Market Share:

While currently without marketed products, Gossamer boasts a pipeline with two lead candidates:

  • GB002: A small-molecule activator currently in Phase 2 trials for the treatment of Gaucher disease, a rare lysosomal storage disorder.
  • GB003: An anti-CD39 monoclonal antibody in Phase 2 trials for the treatment of various cancers.

These products address unmet medical needs in their respective markets, offering potential for significant market share capture upon approval.

Total Addressable Market:

The global market for lysosomal storage disorders is estimated to reach $6.5 billion by 2028. This represents a growing opportunity for Gossamer, considering the unmet needs in this space. Additionally, the global immunotherapy market for cancer treatment is anticipated to reach a staggering $306.5 billion by 2030, further highlighting the potential market potential for GB003.

Financial Performance:

As a clinical-stage company, Gossamer currently generates minimal revenue. Its financial performance is primarily evaluated through cash burn and operating expenses. In 2022, the company reported a net loss of $108.3 million, with a cash burn of approximately $126 million. However, with a strong cash position and ongoing clinical trials, Gossamer is strategically positioned for future commercialization and revenue generation.

Dividends and Shareholder Returns:

Given its clinical-stage status and focus on investment in R&D, Gossamer does not currently pay dividends. The company's main focus is on long-term shareholder value creation through successful product development and commercialization.

Growth Trajectory:

Over the past few years, Gossamer has experienced notable progress in its development programs. GB001 demonstrated promising results in Phase 2a trials for NCL2, while GB002 is advancing through Phase 2 trials for Gaucher disease. These milestones suggest potential for significant growth in the future.

Market Dynamics:

The pharmaceutical industry is characterized by rapid innovation, intense competition, and stringent regulatory requirements. Gossamer actively participates in this dynamic landscape, aiming to differentiate itself through innovative therapies and strategic partnerships.

Competitors:

Gaucher Disease:

  • Sanofi (SNY): Leading competitor with established products like Cerdelga and Cerezyme.
  • Amicus Therapeutics (FOLD): Developing oral therapies like miglustat and Galafold.

NCL2:

  • BioMarin Pharmaceutical (BMRN): Developing Brineura, the only FDA-approved treatment for CLN2.

Cancer Immunotherapy:

  • Bristol Myers Squibb (BMY): A significant player with several approved therapies like Opdivo and Yervoy.
  • Merck & Co. (MRK): Leading contender with Keytruda, a blockbuster immunotherapy drug.

Gossamer differentiates itself by targeting specific and underserved patient populations with novel mechanisms of action.

Potential Challenges and Opportunities:

Challenges:

  • Regulatory hurdles and the lengthy clinical trial process.
  • Demonstrating safety and efficacy of novel therapies.
  • Competition from established pharmaceutical giants.

Opportunities:

  • Growing markets for lysosomal storage disorders and cancer immunotherapy.
  • Strategic partnerships and potential acquisitions.
  • Successful product development and commercialization can drive significant revenue and market share gains.

Recent Acquisitions:

Gossamer Bio has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on an AI-powered analysis of financial health, market standing, and future prospects, Gossamer Bio receives a 7 out of 10 rating. The company demonstrates strong potential, but also carries inherent risks associated with its clinical-stage nature.

Justification:

  • The company enjoys strong financial backing and promising clinical programs.
  • Its focus on underserved patient populations with unmet needs offers a distinct market advantage.
  • However, regulatory uncertainty and market competition remain hurdles to overcome.

Sources:

  • Gossamer Bio website (https://gossamerbio.com/)
  • Securities and Exchange Commission (SEC) filings
  • Market research reports from trusted sources such as Statista and EvaluatePharma

Disclaimers:

The information provided in this overview is intended for informational purposes only and should not be considered investment advice. It is crucial to conduct thorough due diligence and consult with qualified financial professionals before making any investment decisions.

About Gossamer Bio Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2019-02-08
Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain
Sector Healthcare
Industry Biotechnology
Full time employees 135
Full time employees 135

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​